
Biotech Fluidics has replaced its entire DEGASi® stand-alone inline degasser range with a new generation, the DEGASi® NG, which incorporates fifth-generation StabiliX™ vacuum pumps and a redesigned Degasser Vacuum Controller (DVC) across the platform. The rollout simultaneously retires several legacy product lines, including the entire DEGASi® Integration series and the DEGASi® BioCompact, and merges the DEGASi® Plus series directly into the NG family with all product numbers retained.
The timing is not incidental. With the European Chemicals Agency (ECHA) moving its Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) PFAS restriction proposal toward a final committee opinion expected by end of 2026, labs buying or specifying degassing hardware now face a credible near-term obligation to audit fluorinated materials in their flow paths. The DEGASi® LifeSci NG, built around a silicone membrane with no fluorinated wetted materials anywhere in the flow path, is Biotech Fluidics' direct answer to that procurement pressure.
Buyer's note: Existing DEGASi® Plus users will find the transition largely transparent, as Biotech Fluidics has retained external housing dimensions and all product numbers from the Plus series. Labs upgrading individual modules in a multi-instrument environment should confirm firmware and DVC compatibility with their current host system software before ordering, since the standardized error control output is a new electrical interface that older software may not be configured to receive.
The stand-alone inline degasser market divides broadly into two tiers: vacuum degassers bundled as proprietary modules within major high-performance liquid chromatography (HPLC) system platforms, and independent specialist units designed for original equipment manufacturer (OEM) integration or retrofit into any system brand. Biotech Fluidics occupies the specialist tier.
The standardized error control output is a compliance-relevant feature for labs operating under Good Manufacturing Practice (GMP) or Good Laboratory Practice (GLP) frameworks. A degasser that silently underperforms introduces an undetected variable into validated methods. Procurement teams should evaluate whether current data acquisition software can log the error output signal and consider whether the NG platform's fault detection reduces the frequency of required system suitability checks. The LifeSci NG's completely fluorine-free wetted path may also simplify ESG and chemical inventory reporting where PFAS disclosure is becoming a procurement requirement.
Regulated-workflow notice: The DEGASi® NG platform has not been independently claimed as IVD-compliant or FDA 21 CFR Part 11-validated by the manufacturer in publicly available documentation. Labs in regulated environments should request a Declaration of Conformity, full material safety data for wetted components, and clarification on change control documentation before replacing a currently validated degasser with any NG model.
The DEGASi® Analytic NG replaces the discontinued BioCompact with an improved degassing control system and the same metal-free, biocompatible flow path. Instrument developers integrating degassing into surface plasmon resonance (SPR), liquid handling, or microfluidic platforms should assess the open-frame OEM configuration for electrical and spatial fit. The closed-loop DVC with advanced leak detection also reduces field service risk for instruments deployed outside a controlled lab environment.
These labs increasingly face institutional sustainability reporting requirements alongside growing PFAS contamination concerns in sample matrices. The DEGASi® LifeSci NG eliminates any fluorinated wetted material from the flow path entirely and is rated for aqueous solutions at 3–20 mL/min per channel, making it a direct candidate for labs running method development for PFAS in water, food, or biological matrices. Note that it is designed exclusively for neutral aqueous solutions and is not compatible with organic solvents at higher concentrations or pH conditions outside the neutral range.
The DEGASi® Plus product number continuity means existing purchase orders, laboratory information management system (LIMS) records, and calibration logs do not require immediate revision. Core facilities managing inventory across multiple HPLC systems from different vendors will find the NG platform's brand-agnostic design continues to serve mixed-instrument environments well. The ~30% service life extension reduces maintenance call frequency, an operational benefit in cost-recovery environments where instrument downtime has a direct revenue impact.
If your current degasser is approaching the end of its service life, or if your procurement team is beginning to flag PFAS-containing components in the instrument supply chain, the DEGASi® NG platform warrants evaluation before your next purchase decision. Contact Biotech Fluidics directly for model selection guidance based on your specific flow rates and solvent chemistry. Full product details and the complete NG range are available at biotechfluidics.com.
This article draws on a Biotech Fluidics press release dated September 6, 2026 and was created with the assistance of Generative AI and has undergone editorial review before publishing. LabX's editorial policy can be found here.